Sporex

# Sporex ## Overview - **Classification**: Novel Broad-Spectrum Antifungal - **Mechanism**: Sporex inhibits fungal cell wall synthesis by selectively targeting a key fungal-specific enzyme, leading to osmotic instability and cell lysis. ## Primary Indications 1. **Invasive Candidiasis** - Treatment of serious infections caused by *Candida* species. 2. **Invasive Aspergillosis** - Management of severe infections by *Aspergillus* species. 3. **Coccidioidomycosis** - Treatment of severe or disseminated infections. ## Adult Dosing ### Standard Dosing **Invasive Candidiasis/Aspergillosis (Loading Dose)** - **Dose**: **200 mg** - **Frequency**: Once daily on Day 1 - **Route**: Intravenous (IV) infusion **Invasive Candidiasis/Aspergillosis (Maintenance Dose)** - **Dose**: **100 mg** - **Frequency**: Once daily (starting Day 2) - **Route**: Intravenous (IV) infusion or Oral (PO) - **Duration**: Typically 14 days or until resolution of symptoms **Coccidioidomycosis** - **Dose**: **150 mg** - **Frequency**: Once daily - **Route**: Oral (PO) - **Duration**: Minimum 6-12 months, based on clinical response ### Dose Adjustments - **Renal Impairment**: - CrCl 30-50 mL/min: No adjustment needed. - CrCl <30 mL/min: **Reduce maintenance dose to 75 mg daily**. - Hemodialysis: Administer after dialysis. - **Hepatic Impairment**: - Mild (Child-Pugh A): No adjustment. - Moderate (Child-Pugh B): **Reduce maintenance dose to 50 mg daily**. - Severe (Child-Pugh C): **Contraindicated**. - **Elderly Patients**: No specific dose adjustment solely based on age; monitor renal function. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **5 mg/kg** - **Frequency**: Every 24 hours - **Route**: Intravenous (IV) infusion - **Maximum**: **50 mg/dose** - **Special Notes**: Monitor LFTs closely; limited data in this age group. ### Infants (1-12 months) - **Dose**: **7 mg/kg** - **Frequency**: Every 24 hours - **Route**: Intravenous (IV) or Oral (PO, oral suspension preferred) - **Maximum**: **100 mg/dose** ### Children (1-12 years) - **Dose**: **8 mg/kg** - **Frequency**: Every 24 hours - **Route**: Oral (PO, tablets or suspension) - **Maximum**: **200 mg/dose** (Do not exceed adult loading dose) ### Adolescents (13-18 years) - **Dose**: **Adult dosing applies** for most indications. - **Maximum**: **Adult dose** (e.g., 200 mg loading, 100 mg maintenance). - **Special Notes**: Consider weight, pubertal status, and renal function. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Sporex or its excipients. - **Absolute**: Severe hepatic impairment (Child-Pugh C). - **Absolute**: Co-administration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine). ### Common Adverse Effects - **Very Common (>10%)**: Nausea, vomiting, headache. - **Common (1-10%)**: Diarrhea, abdominal pain, rash, elevated liver enzymes (AST/ALT). - **Serious but Rare**: Hepatotoxicity (severe), QT prolongation, Stevens-Johnson syndrome. ### Key Drug Interactions - **CYP3A4 Inducers (e.g., rifampin, phenytoin)**: Decreases Sporex levels; **contraindicated**. - **CYP3A4 Inhibitors (e.g., azoles, ritonavir)**: Increases Sporex levels; **monitor for toxicity, consider dose reduction**. - **Drugs that prolong QT interval (e.g., amiodarone, quinidine)**: Additive QT prolongation risk; **avoid co-administration or monitor ECG closely**. - **Statins**: Increased statin levels, leading to myopathy/rhabdomyolysis; **consider statin dose reduction or temporary discontinuation**. ## Monitoring & Follow-up - **Before Treatment**: Baseline Liver Function Tests (LFTs), renal function (Cr, BUN), and ECG. - **During Treatment**: - LFTs: Weekly for the first 2 weeks, then monthly. - Renal Function: Weekly if CrCl <30 mL/min or in critically ill patients. - ECG: If concurrent QT-prolonging drugs or cardiac risk factors. - Therapeutic Drug Monitoring (TDM): Consider for severe infections or in patients with altered pharmacokinetics. - **Clinical Signs**: Monitor for signs of hepatotoxicity (jaundice, dark urine), rash, or cardiac symptoms. ## Clinical Pearls - 💡 **Oral Absorption**: Oral Sporex is best absorbed with a high-fat meal to maximize bioavailability. - 💡 **Infusion Rate**: Administer IV infusion slowly over at least 60 minutes to prevent infusion-related reactions. - 💡 **Patient Counseling**: Emphasize completing the full course of therapy, even if symptoms improve, to prevent relapse and resistance. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.